Reported Earnings • May 16
First quarter 2026 earnings released: EPS: NT$0.20 (vs NT$0.35 loss in 1Q 2025) First quarter 2026 results: EPS: NT$0.20 (up from NT$0.35 loss in 1Q 2025). Revenue: NT$217.1m (up 81% from 1Q 2025). Net income: NT$21.0m (up NT$56.7m from 1Q 2025). Profit margin: 9.7% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • May 05
Applied BioCode Announces FDA Clearance for KingFisher™ Nucleic Acid Extraction with BioCode® Respiratory Pathogen Panel for IVD Use Applied BioCode, a leader in multiplex molecular diagnostic solutions, announced a significant enhancement to its BioCode Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic acid extraction claims for the widely used Thermo Fisher Scientific KingFisher Flex platform. This expansion provides clinical laboratories running BioCode RPP with greater workflow flexibility and optimized sample processing capabilities. This enhancement to the BioCode RPP enables seamless integration of the KingFisher Flex extraction platform and the BioCode MDx-3000 automated detection system, expanding the panel’s utility and increasing throughput for respiratory testing. Clinical laboratories using these extraction systems can now streamline their workflows by pairing them with the BioCode RPP, providing an affordable and comprehensive solution for detecting 17 prevalent respiratory pathogens. By improving workflow efficiency, this new claim is expected to enhance patient care by accelerating the delivery of accurate and timely diagnostic results. This submission builds on Applied BioCode’s previous FDA clearance of the BioCode Gastrointestinal Pathogen Panel (GPP) with the KingFisher Flex system, highlighting the company’s ongoing success in validating flexible, high-throughput extraction solutions across its multiplexed panel portfolio. Applied BioCode continues to advance molecular diagnostic solutions that meet the evolving needs of clinical laboratories, supporting patient care with accurate, reliable, and actionable results. Reported Earnings • Mar 13
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: NT$1.96 loss per share (improved from NT$2.88 loss in FY 2024). Revenue: NT$475.2m (up 39% from FY 2024). Net loss: NT$201.2m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year. Announcement • Mar 12
Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026 Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026, at 10:00 Taipei Standard Time. Location: 7 floor no,185, hsin hu 1st rd., neihu district, taipei city Taiwan Board Change • Dec 30
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jim Wu was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 12
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: NT$0.33 loss per share (improved from NT$0.80 loss in 3Q 2024). Revenue: NT$122.8m (up 64% from 3Q 2024). Net loss: NT$33.7m (loss narrowed 56% from 3Q 2024). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 23%. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 8% per year. Reported Earnings • Aug 27
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: NT$0.66 loss per share (further deteriorated from NT$0.61 loss in 2Q 2024). Revenue: NT$115.9m (up 14% from 2Q 2024). Net loss: NT$67.5m (loss widened 35% from 2Q 2024). Revenue missed analyst estimates by 7.3%. Earnings per share (EPS) also missed analyst estimates by 53%. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Announcement • Jun 07
Applied BioCode Corporation Approves Board Elections Applied BioCode Corporation at its 2025 Shareholders' General Meeting held on June 6, 2025, approved the election of George J. Lee, Director, Foresee Pharmaceuticals Co. Ltd. and Benjamin Jen, Managing Partner, GRC SinoGreen Fund as Directors. Title and name of the previous position holder: Representative of institutional directors: Independent Director: Ben Liu, Lawyer, InfoShare Tech Law Office and Independent Director: Jack Hsiao, COO, Hsiao Chung-Cheng Healthcare group. Title and name of the new position holder: Representative of institutional directors: Independent Director: James Hsu, Director, TaChuan Investment Ltd. and Independent Director: Jim Wu, Director and Chief Corporate Affairs Officer, TNL Mediagene. Effective date of the new appointment is June 6, 2025. Reported Earnings • May 15
First quarter 2025 earnings released: NT$0.35 loss per share (vs NT$0.77 loss in 1Q 2024) First quarter 2025 results: NT$0.35 loss per share (improved from NT$0.77 loss in 1Q 2024). Revenue: NT$120.0m (up 47% from 1Q 2024). Net loss: NT$35.7m (loss narrowed 43% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Announcement • May 01
Applied BioCode Corporation to Report Q1, 2025 Results on May 08, 2025 Applied BioCode Corporation announced that they will report Q1, 2025 results on May 08, 2025 Reported Earnings • Mar 20
Full year 2024 earnings released: NT$2.88 loss per share (vs NT$2.01 loss in FY 2023) Full year 2024 results: NT$2.88 loss per share (further deteriorated from NT$2.01 loss in FY 2023). Revenue: NT$343.1m (down 13% from FY 2023). Net loss: NT$260.8m (loss widened 59% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. Announcement • Mar 14
Applied BioCode Corporation, Annual General Meeting, Jun 06, 2025 Applied BioCode Corporation, Annual General Meeting, Jun 06, 2025. Announcement • Mar 06
Applied BioCode Corporation to Report Q4, 2024 Results on Mar 13, 2025 Applied BioCode Corporation announced that they will report Q4, 2024 results at 9:00 AM, Taipei Standard Time on Mar 13, 2025 Announcement • Jan 14
Applied Biocode Announces New Nucleic Acid Extraction Claim for Kingfisher Flex Nucleic Acid Purification System with Biocode Gastrointestinal Pathogen Panel (GPP) Applied BioCode announced a significant enhancement to its BioCode Gastrointestinal Pathogen Panel (GPP) with the addition of nucleic acid extraction claim for the widely adopted ThermoFisher Scientific KingFisher Flex platform. This expansion enables greater workflow flexibility and optimized sample processing capabilities for clinical laboratories running the BioCode GPP. This enhancement to the BioCode GPP allows for seamless integration with KingFisher Flex extraction platform, broadening the panel’s utility and increasing throughput for gastrointestinal testing. Clinical laboratories using these extraction systems can now streamline their operations by pairing them with the BioCode GPP, providing a comprehensive solution to detect 17 of the most prevalent gastrointestinal pathogens. By improving workflow efficiency, the new claim is expected to significantly impact patient care by accelerating the turnaround of accurate and timely diagnostic information. The BioCode GPP now supports multiple extraction platforms, making it one of the most versatile panels in its class for detecting gastrointestinal pathogens in stool samples. This addition aligns with Applied BioCode’s mission to innovate and adapt to the growing demands of healthcare providers, enabling laboratories to maximize the value of their existing instruments while advancing diagnostic capabilities. With its unique Barcoded Magnetic Bead (BMB) technology, the BioCode GPP simplifies and accelerates high-throughput molecular diagnostics, offering an economical, accurate, and comprehensive solution for clinical labs across the U.S. and beyond. This nucleic acid extraction expansion will help laboratories improve their workflows, increase operational flexibility, and expand their diagnostic capabilities. New Risk • Nov 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$2.29b market cap, or US$70.4m). Reported Earnings • Nov 18
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: NT$0.80 loss per share (further deteriorated from NT$0.54 loss in 3Q 2023). Revenue: NT$74.9m (down 29% from 3Q 2023). Net loss: NT$76.8m (loss widened 76% from 3Q 2023). Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 82%. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 10% per year. Announcement • Nov 02
Applied BioCode Corporation to Report Q3, 2024 Results on Nov 11, 2024 Applied BioCode Corporation announced that they will report Q3, 2024 results on Nov 11, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: NT$0.61 loss per share (improved from NT$0.75 loss in 2Q 2023). Revenue: NT$101.6m (up 30% from 2Q 2023). Net loss: NT$50.0m (loss narrowed 18% from 2Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 11%. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 14% per year. Announcement • Aug 15
Applied BioCode Corporation to Report Q2, 2024 Results on Aug 22, 2024 Applied BioCode Corporation announced that they will report Q2, 2024 results on Aug 22, 2024 Announcement • Jul 20
Applied BioCode Corporation announced that it has received funding Applied BioCode Corporation announced a private placement to issue common shares on July 19, 2024. The transaction has been approved by shareholders of company. New Risk • Jun 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$84.8m). Reported Earnings • May 19
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: NT$0.77 loss per share (further deteriorated from NT$0.62 loss in 1Q 2023). Revenue: NT$81.5m (down 1.5% from 1Q 2023). Net loss: NT$63.1m (loss widened 24% from 1Q 2023). Revenue missed analyst estimates by 9.4%. Earnings per share (EPS) also missed analyst estimates by 71%. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Announcement • Apr 15
Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only Applied BioCode Inc. announced the launch of its latest innovation, the BioCode STI + Resistance Panel (RUO). This multiplex nucleic acid amplification test is meticulously crafted to qualitatively detect DNA from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), as well as macrolide-resistant and fluoroquinolone-resistant single nucleotide polymorphism (SNP) mutations in a single reaction. The panel is exclusively intended for research purposes and is not intended for diagnostic procedures. Engineered with precision for seamless integration with the BioCode MDx-3000 automated system, it delivers timely test results approximately 4 hours post-DNA extraction. The system boasts an intuitive protocol and reporting software, meticulously tailored to enhance workflows in research clinical microbiology lab environments, accommodating up to 96 samples per test run. Announcement • Mar 22
Applied BioCode Announces CEO Changes Applied BioCode announced the retirement of Chris Bernard as Chief Executive Officer. Chris Bernard has served as CEO for the past two years and has been instrumental in guiding the company through a period of growth and innovation. During his tenure, Chris played a pivotal role in advancing Applied BioCode’s strategic initiatives and driving the company’s commitment to delivering cutting-edge solutions to the molecular diagnostics market. His leadership and dedication have been invaluable in positioning Applied BioCode as a leader in multiplex testing technologies. Following his retirement, Winston Ho, Ph.D., Founder and President, will step into the role of Chief Executive Officer until a new CEO is appointed. Reported Earnings • Mar 17
Full year 2023 earnings released: NT$2.01 loss per share (vs NT$2.26 loss in FY 2022) Full year 2023 results: NT$2.01 loss per share (improved from NT$2.26 loss in FY 2022). Revenue: NT$395.2m (up 1.2% from FY 2022). Net loss: NT$164.2m (loss narrowed 11% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year and the company’s share price has also fallen by 23% per year. Announcement • Mar 08
Applied BioCode Corporation, Annual General Meeting, May 27, 2024 Applied BioCode Corporation, Annual General Meeting, May 27, 2024. Location: Lily Conference, (2F, No. 327, Sec. 1, Tiding Blvd., Neihu Dist Taipei City Taiwan Agenda: To consider 2023 operation report; to consider audit committee review report on the 2023 financial statements; to consider amendment to the rules of procedures for the board of directors meeting; to consider 2023 business report and 2023 consolidated financial report; to consider 2023 deficit compensation; to consider adoption of the amended and restated memorandum and articles of association; to consider amendment to procedures for acquisition or disposal of assets; and to consider other issues. New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$67.8m). Reported Earnings • Nov 15
Third quarter 2023 earnings released: NT$0.53 loss per share (vs NT$0.54 loss in 3Q 2022) Third quarter 2023 results: NT$0.53 loss per share (improved from NT$0.54 loss in 3Q 2022). Revenue: NT$105.8m (down 1.9% from 3Q 2022). Net loss: NT$43.7m (flat on 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Announcement • Sep 29
Applied BioCode Appoints Beth Laderman as Chief Scientific Officer Applied BioCode announced that Beth Laderman has been appointed as their new Chief Scientific Officer signaling a significant step in the company’s expansion. With 25 years of experience in the medical diagnostic field, Dr. Laderman brings expertise from her previous roles at HYCOR Biomedical and Biomerica Inc. Her appointment is set to drive Applied BioCode’s focus on expanding its MDx-3000 platform and exploring new applications for its patented barcoded magnetic beads (BMBs). Dr. Laderman joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology. With its current portfolio of PCR-based, multiplex molecular diagnostic assays in the respiratory and gastrointestinal markets, along with the new BioCode Fungal Panel RUO approval, the company remains steadfast in its mission in having R&D fully support the commercial enterprise by delivering transformative solutions for high-throughput diagnostics. Dr. Laderman’s appointment as CSO of Applied BioCode marks an exciting chapter in the company’s journey to revolutionize diagnostics and life sciences. Her deep knowledge, leadership skills, and dedication to innovation are expected to drive the company’s research and development initiatives to new heights. Announcement • Sep 25
Applied BioCode Corporation Announces the Resignation of Michael Sean Aye as Research and Development Officer Applied BioCode Corporation announced the resignation of Michael Sean Aye as research and development officer, effective September 23, 2023. Reason for the change: Personal career planning. Reported Earnings • Aug 30
Second quarter 2023 earnings released: NT$0.75 loss per share (vs NT$0.39 loss in 2Q 2022) Second quarter 2023 results: NT$0.75 loss per share (further deteriorated from NT$0.39 loss in 2Q 2022). Revenue: NT$78.5m (down 27% from 2Q 2022). Net loss: NT$61.2m (loss widened 94% from 2Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • Jun 15
Applied BioCode Corporation Announces the Change of Representative of Institutional Director Applied BioCode Corporation announced Name of the previous position holder:Wen-Chin Hung. Resume of the previous position holder:Wen-Chin Hung/Mingwei Corporation. 5.Name of the new position holder:Lizzie lee. Resume of the new position holder:Lizzie Lee/GRC SinoGreen Capital Co. Ltd. Risk Management Director. Reason for the change: Institutional director assigned a representative. Announcement • Jun 13
Applied Biocode Corporation Announces the Launch of the Fungal Panel Assay for Research Use Applied BioCode Corporation announced that it now offers Fungal Panel on the BioCode® MDx-3000 system for research use only (RUO). The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples. This Panel detects fungal agents includingAspergillus species, Rhizopus, Mucor, Rhizomucor, Cunninghamella, Lomentospora, Fusarium, Cryptococcus, Pneumocystis jirovecii and dimorphic pathogens (Coccidioides immitis/posadasii, Histoplasma capsulatum and Blastomyces dermatiditis). The panel will provide 20 distinct results along with an internal control and will be primarily for use on the company's BioCode MDx-3000 instrument. Detection of IFI is difficult, and recovery by culture could take several days to weeks with poor sensitivity. Faster and more sensitive detection of IFI can be helpful in clinical management, especially for immunocompromised patients. Reported Earnings • Mar 26
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Full year 2022 results: NT$2.26 loss per share (further deteriorated from NT$2.02 loss in FY 2021). Revenue: NT$390.3m (up 22% from FY 2021). Net loss: NT$184.7m (loss widened 12% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Jan 05
Applied BioCode Corporation Announces Resignation of Craig Griz Adams as Sales Director Applied BioCode Corporation announced resignation of Craig Griz Adams as Sales Director due to personal career planning, effective January 4, 2023. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 18
Applied BioCode Corporation Announces Change of Sales Director Applied BioCode Corporation announced change of Sales Director. Name, title, and resume of the previous position holder: Michael Jason Scott/Sales Director. Type of the change: Resignation. Effective date is May 17, 2022. Reported Earnings • May 14
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: NT$0.90 loss per share (down from NT$0.29 loss in 1Q 2021). Revenue: NT$54.1m (down 36% from 1Q 2021). Net loss: NT$73.8m (loss widened 209% from 1Q 2021). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to NT$34.00 Down from NT$102, the current price target is provided by 1 analyst. New target price is 27% below last closing price of NT$46.75. Stock is down 8.5% over the past year. The company is forecast to post a net loss per share of NT$2.24 next year compared to a net loss per share of NT$2.02 last year. Reported Earnings • Mar 31
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: NT$2.02 loss per share (down from NT$1.33 loss in FY 2020). Revenue: NT$320.0m (up 7.0% from FY 2020). Net loss: NT$165.2m (loss widened 60% from FY 2020). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 15%. Over the next year, revenue is forecast to stay flat compared to a 31% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Dec 17
Applied BioCode Obtains Emergency Use Authorization for CoV-2 Flu Plus Assay Applied BioCode announced that it has received Emergency Use Authorization (EUA) from the US FDA for its BioCode® CoV-2 Flu Plus Assay. This PCR-based, multiplex molecular diagnostic assay can simultaneously detect and differentiate between SARS-CoV-2, Influenza A with subtypes (seasonal H1, 2009 H1N1, H3, Influenza B), and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens. The test is designed to assist physicians in evaluating patients with clinical signs and symptoms respiratory infection. The BioCode® CoV-2 Flu Plus Assay is Applied BioCode’s third EUA authorization from the US FDA for COVID-19 testing. Applied BioCode previously received FDA EUA authorization for the BioCode® SARS CoV-2 Assay and for pooling of up to 5 samples for that assay. The BioCode® CoV-2 Flu Plus Assay is run on the automated high-throughput BioCode® MDx-3000 Molecular System and provides scalable throughput, allowing clinical labs to run up to 564 sample results per day. BioCode® CoV-2 Flu Plus Assay builds on the existing portfolio of high-throughput syndromic assays from Applied BioCode including the FDA 510(k) cleared BioCode Respiratory Pathogen Panel (17 targets), FDA 510(k) cleared BioCode® Gastrointestinal Pathogen Panel (17 targets), and its stand-alone EUA authorized BioCode® SARS-CoV-2 Assay. Announcement • Nov 24
Applied BioCode Launches 28 New Fungal Analyte Specific Reagents in the US Applied BioCode announced that it has released28 Fungal Analyte Specific Reagents (ASRs) for use in molecular tests. (15 ASRs for mold pathogens, 10 ASRs for yeast pathogens, and 3 ASRs to detect dimorphic fungi). These ASR products utilize the company’s proprietary Barcoded Magnetic Bead (BMB) technology for specific detection of targeted organisms. For use as building blocks to develop and validate tests for the diagnosis of infectious diseases, ASRs may be sold to in vitro diagnostic manufacturers, and clinical laboratories regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), as qualified to perform high complexity testing. ASRs may also be sold to organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other nonclinical laboratories. The primer pairs or probes coupled to BMBs are classified as ASRs, which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs). Reported Earnings • Nov 12
Third quarter 2021 earnings released: NT$0.75 loss per share (vs NT$0.28 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: NT$58.8m (down 40% from 3Q 2020). Net loss: NT$61.1m (loss widened 165% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 30
Full year 2020 earnings released: NT$1.33 loss per share (vs NT$4.36 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$299.0m (up 186% from FY 2019). Net loss: NT$103.5m (loss narrowed 63% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Mar 18
Applied BioCode Corporation, Annual General Meeting, Jun 07, 2021 Applied BioCode Corporation, Annual General Meeting, Jun 07, 2021. Is New 90 Day High Low • Feb 02
New 90-day low: NT$49.05 The company is down 38% from its price of NT$79.60 on 04 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 10.0% over the same period. Is New 90 Day High Low • Jan 07
New 90-day low: NT$55.00 The company is down 48% from its price of NT$106 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period. Is New 90 Day High Low • Dec 02
New 90-day low: NT$72.70 The company is down 48% from its price of NT$139 on 03 September 2020. The Taiwanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: NT$0.28 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$97.4m (up 191% from 3Q 2019). Net loss: NT$23.1m (loss narrowed 67% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year. Is New 90 Day High Low • Oct 28
New 90-day low: NT$77.80 The company is down 24% from its price of NT$102 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period. Is New 90 Day High Low • Oct 13
New 90-day low: NT$92.50 The company is down 19% from its price of NT$114 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 16% over the same period. Announcement • Jul 22
Applied BioCode Corporation To Be Deleted From Other OTC Applied BioCode Corporation Corp. Common Stock will be deleted from Other OTC effective July 13, 2020. The deletion was due to Inactive Security. 
